King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia
RIYADH, Saudi Arabia, May 09, 2024 (GLOBE NEWSWIRE) -- Harvard University -- Eight years into Vision 2030, Saudi Arabia has made significant strides with digital innovations and enhanced access to quality care. Strategic investments in infrastructure, technology, and talent, have led to advancements revolutionizing patient care delivery and elevating the standards of healthcare locally. These efforts have notably raised the average life expectancy, reduced mortality rates, and enhanced overall well-being across the Kingdom.
Central to these achievements, King Faisal Specialist Hospital & Research Centre (KFSH&RC), renowned for its specialized care and treatments across critical fields such as oncology, cardiology, organ transplantation, and genetics has positioned itself as a leader in specialized patient care, taking the charge towards a brighter, healthier future for the Kingdom. Through its commitment to pioneering digital health initiatives, comprehensive educational programs, and novel research endeavors, it is reshaping the local landscape, and setting new standards of efficiency and accessibility.
In an era defined by technological advancements, and with the Kingdom’s push towards digitalization, KFSH&RC stands at the forefront of digital health integration among its local peers, leveraging cutting-edge telemedicine services, virtual consultations, and AI-driven tools such as the ANFAL AI System that transforms patient outcomes through predictive insights and personalized care, ensuring the best outcomes for patient satisfaction.
KFSH&RC’s digital health initiatives extend to addressing broader health threats through technologies such as Whole Genomic Sequencing (WGS) and Advanced Radiation Therapy. The hospital has also pioneered organ transplantation by performing the world's first fully robotic liver transplant and introduced to the region innovations like the Harmony Transcatheter Pulmonary Valve (TPV), enhancing patient recovery and experience. These technologies facilitate personalized treatment plans and improve the accuracy and speed of medical diagnostics, contributing significantly to the elevation of patient care standards and a sustainable, resilient healthcare infrastructure in line with the objectives of the Health Sector Transformation Program.
KFSH&RC continues to push the boundaries of medical research addressing pressing health challenges and contributing to Saudi Arabia’s public health landscape, with discoveries like the PfAP2-MRP gene crucial for malaria treatment and the identification of the new Riyadhensis bacteria strain. These discoveries have not only improved diagnostic accuracy but also facilitated early interventions, ensuring timely and effective patient support, in line with the national objectives to reduce chronic disease prevalence.
These comprehensive efforts are supported by KFSH&RC’s robust educational initiatives, which prepare the next generation of medical professionals through training programs and international collaborations.
Recognized by ‘Brand Finance’ in 2024 as the most valuable healthcare brand in Saudi Arabia and the Middle East for the second consecutive year, placing 9th in Saudi Arabia and 28th in the Middle East. Additionally, KFSH&RC stands out as the only hospital worldwide to be ranked among its country's top ten most valuable brands.
About King Faisal Specialist Hospital & Research Centre (KFSH&RC):
King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.
In 2024, "Brand Finance" ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally for the second consecutive year. Additionally, in 2024, it was recognized as one of the leading global healthcare providers by Newsweek magazine.
As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.
CONTACT INFORMATION
For more information, please contact:
Mr. Essam Al-Zahrani, Media Affairs Head, 0555254429
Mr. Abdullah Al-Aown, Media Coordination Officer, 0556294232
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/003e76ab-3d93-42d4-9edf-5e652a14c559
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Start of construction work on the Uus-Kindrali20.5.2024 09:52:00 CEST | Press release
Start of construction work on the Uus-Kindrali Pro Kapital has started the construction of the next phase of the Kindrali Houses project in Tallinn Kristiine City. The building at Talli 3/Sammu 8, which is part of the Uus-Kindrali project, will comprise 90 apartments and one commercial unit. The new phase of Kindrali Houses will consist of a 7-storey building with 1-5 bedroom apartments. To date, 31% of the apartments have already been pre-sold, which was the incentive to start construction work. Uus-Kindrali, with its modern and Scandinavian architecture, will be built in Kristiine City and will be framed by a tree-lined avenue and Brooklyn-style high ground floor homes and commercial space opening directly onto the street. On the other side, between the buildings is a spacious and private courtyard with fruit trees, berry bushes, cozy seating and play areas, offering joy and activity for everyone. The architects of the buildings and landscape of the Uus-Kindrali is Allianss Arhitekti
Vaisala selected to deliver 18 weather radars to the State Meteorological Agency of Spain20.5.2024 09:15:00 CEST | Press release
Vaisala Press release May 20, 2024 Vaisala selected to deliver 18 weather radars to the State Meteorological Agency of Spain The new radars enhance the accuracy of weather data in Spain and the capability to predict extreme weather events, such as severe storms, in Southern Europe. The value of the project is approximately EUR 25 million, making it the largest-ever order for Vaisala. Vaisala, a global leader in measurement technology, has won the tendering of delivering a new weather radar system to the Spanish State Meteorological Agency (AEMET), which is an organization under the Ministry of Environment of the country (MITECO). The value of the project is approximately EUR 25 million, making it the largest single order for Vaisala ever. The contract will be signed after the public procurement appeal period has ended, and the order will be booked to Vaisala's orders received after the contract has been finalized. The contract includes 18 dual-polarization C-band weather radars (WRM200
Municipality Finance issues a EUR 75 million tap under its MTN programme20.5.2024 09:00:00 CEST | Press release
Municipality Finance Plc Stock exchange release 20 May 2024 at 10:00 am (EEST) Municipality Finance issues a EUR 75 million tap under its MTN programme On 21 May 2024 Municipality Finance Plc issues a new tranche in an amount of EUR 75 million to an existing benchmark issued on 26 April 2023. With the new tranche, the aggregate nominal amount of the benchmark is EUR 1.375 billion. The maturity date of the benchmark is 29 July 2030. The benchmark bears interest at a fixed rate of 3.125 % per annum. The new tranche is issued under MuniFin’s EUR 50 billion programme for the issuance of debt instruments. The offering circular, the supplemental offering circular and final terms of the notes are available in English on the company's website at https://www.kuntarahoitus.fi/en/for-investors. MuniFin has applied for the new tranche to be admitted to trading on the Helsinki Stock Exchange maintained by Nasdaq Helsinki. The public trading is expected to commence on 21 May 2024. The existing notes
DNA Plc: Changes in Executive Team20.5.2024 09:00:00 CEST | Press release
DNA PLC STOCK EXCHANGE RELEASE 20 MAY 2024 AT 10:00 DNA Plc’s SVP, Corporate Affairs (CCAO) and member of the Executive Team, Asta Rantanen, will retire effective 31 July. Master of Laws Vesa Vuoti has been appointed as her successor and member of DNA’s Executive Team as of 1 August. Vuoti has had a long career at DNA in a number of roles, most recently as VP, Legal and Regulatory Affairs. Previously, he has served as Director of Administration and Security, among others. Ph.D., CIO Sari Leppänen is appointed CTO for DNA. Since the beginning of May, she has temporarily managed that position alongside her own work after the previous CTO Ville Virtanen transferred to DNA’s parent company, Telenor. In addition to the new role, Leppänen will continue as the CIO for DNA. “I would like to thank Asta Rantanen for her great work at DNA over the past twenty years, first in several legal roles and later also as SVP of Corporate Affairs. Asta has developed DNA’s corporate governance policies rema
The subscription period for the warrants of series TO7 starts today, May 20, 202420.5.2024 08:30:00 CEST | Press release
Today, May 20, 2024, marks the commencement of the exercise period for subscription of warrants of series TO7 in Terranet AB (publ) (”Terranet” or the” Company”). The exercise period for warrants of series TO7 runs up until and including June 3, 2024. Each warrant gives the right to subscribe for one (1) new share of series B in the Company to the price of SEK 0.073 per share. The invested amount must be rounded up to two decimal places. For the warrants not to expire without value, the owner must actively subscribe for new shares no later than June 3, 2024, alternatively sell their warrants no later than May 29, 2024. Please observe that certain nominees might close their application period earlier than June 3, 2024. The letter to holders of warrants of series TO7 is available on the Company's website www.terranet.se. Summarized terms for the warrants of series TO7: Subscription period: May 20, 2024 – June 3, 2024. Issue size: 182,664,660 warrants of series TO7, which entitles to subs